BT-001 is an armed oncolytic virus expressing an anti-CTLA4 and GM-CSF antibody, from the Invir.IO® platform.
It has been evaluated in a Phase 1/2a multicenter, open label, dose-escalation study as a single agent and in combination with pembrolizumab* in solid tumors after intratumoral administration.